ribociclib
novartis
['kisqali', 'breast', 'novartis']
 new cdk4/6i data at asco reinforce novartis kisqali as only drug in class with consistently proven overall survival benefit in hr+/her2- metastatic breast cancer
Free Online Press Release Distribution Service For Business